Per Wold-Olsen
Retired President,
Human Health Intercontinental Division, Merck & Co., Inc.

Mr. Wold-Olsen joined Gilead’s Board of Directors in January 2010 after serving as the Chair of the company’s Health Policy Advisory Board since 2007. From 2005 to 2006, Mr. Wold-Olsen served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a leading global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck & Co.,Inc. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S. He also serves as a director of Novo A/S. Mr. Wold-Olsen is the Chair of the Board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria. Mr. Wold-Olsen previously served as a director of PharmaNet Development Group, Inc., Royal Duch Numico, Exicon A/S and H. Lundbeck A/S. In his more than 30-year career at Merck, Mr. Wold-Olsen held various leadership positions within the company with responsibility for 15,000 employees in more than 100 markets in Europe, Eastern Europe, Middle East/Africa, India, Latin America and Canada. Mr. Wold-Olsen received MBAs in Economics/Administration from the Norwegian School of Management and in Management/Marketing from the University of Wisconsin.

NASDAQ (US Dollar)
$80.91
 Stock is Up 1.51 (1.90%)
Data as of 02/23/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Gilead Sciences at the RBC Capital Markets 2018 Global Healthcare Conference

February 21, 2018 9:00 a.m. ET
Play
Fourth Quarter 2017 Gilead Sciences Earnings Conference Call

February 06, 2018 4:30 p.m. ET
Play
36th Annual J.P. Morgan Healthcare Conference

January 08, 2018 3:30 p.m. PT
Play
Credit Suisse 26th Annual Healthcare Conference

November 07, 2017 12:30 p.m. MT
Play